3,007
Views
6
CrossRef citations to date
0
Altmetric
Real World Evidence

Comprehensive assessment of patients with irritable bowel syndrome with constipation and chronic idiopathic constipation using deterministically linked administrative claims and patient-reported data: the Chronic Constipation and IBS-C Treatment and Outcomes Real-World Research Platform (CONTOR)

, , , , , , , & show all
Pages 1072-1083 | Received 09 Apr 2020, Accepted 10 Jul 2020, Published online: 11 Aug 2020

References

  • Lacy BE, Mearin F, Chang L, et al. Bowel disorders. Gastroenterology. 2016;150(6):1393.e5–1407.e5.
  • Irvine EJ, Ferrazzi S, Pare P, et al. Health-related quality of life in functional GI disorders: focus on constipation and resource utilization. Am J Gastroenterology. 2002;97(8):1986–1993.
  • Dean BB, Aguilar D, Barghout V, et al. Impairment in work productivity and health-related quality of life in patients with IBS. Am J Manag Care. 2005;11(1 Suppl):S17–S26.
  • Ballou S, McMahon C, Lee HN, et al. Effects of irritable bowel syndrome on daily activities vary among subtypes based on results from the IBS in America survey. Clin Gastroenterol Hepatol. 2019;17(12):2471.e3–2478.e3.
  • Doshi JA, Cai Q, Buono JL, et al. Economic burden of irritable bowel syndrome with constipation: a retrospective analysis of health care costs in a commercially insured population. J Manag Care Spec Pharm. 2014;20(4):382–390.
  • Cai Q, Buono JL, Spalding WM, et al. Healthcare costs among patients with chronic constipation: a retrospective claims analysis in a commercially insured population. J Med Econ. 2014;17(2):148–158.
  • Reilly MC, Bracco A, Ricci JF, et al. The validity and accuracy of the Work Productivity and Activity Impairment Questionnaire–Irritable Bowel Syndrome version (WPAI:IBS). Aliment Pharmacol Ther. 2004;20(4):459–467.
  • Dennison C, Prasad M, Lloyd A, et al. The health-related quality of life and economic burden of constipation. Pharmacoeconomics. 2005;23(5):461–476.
  • Quigley EMM, Horn J, Kissous-Hunt M, et al. Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Irritable Bowel Syndrome with Constipation (BURDEN IBS-C) study: results of an online questionnaire. Adv Ther. 2018;35(7):967–980.
  • Harris LA, Horn J, Kissous-Hunt M, et al. The Better Understanding and Recognition of the Disconnects, Experiences, and Needs of Patients with Chronic Idiopathic Constipation (BURDEN-CIC) study: results of an online questionnaire. Adv Ther. 2017;34(12):2661–2673.
  • Johnson CL, Dohmann SM, Burt VL, et al. National health and nutrition examination survey: sample design, 2011–2014. National Center for Health Statistics. Vital Health Stat. 2014;2:162.
  • American Association for Public Opinion Research. Standard definitions: final dispositions of case codes and outcome rates for surveys. 9th ed. 2016 [Accessed 2019 Sep 17]. Available from: http://www.aapor.org/AAPOR_Main/media/publications/Standard-Definitions20169theditionfinal.pdf.
  • Frank L, Kleinman L, Farup C, et al. Psychometric validation of a constipation symptom assessment questionnaire. Scand J Gastroenterol. 1999;34(9):870–877.
  • Marquis P, De La Loge C, Dubois D, et al. Development and validation of the patient assessment of constipation quality of life questionnaire. Scand J Gastroenterol. 2005;40(5):540–551.
  • Reilly MC, Zbrozek AS, Dukes EM. The validity and reproducibility of a work productivity and activity impairment instrument. Pharmacoeconomics. 1993;4(5):353–365.
  • Quan H, Li B, Couris CM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682.
  • US Bureau of Labor Statistics. Consumer price index. Medical care; 2014 [Accessed 2017]. Available from https://www.bls.gov/cpi/data.htm.
  • Johanson JF, Kralstein J. Chronic constipation: a survey of the patient perspective. Aliment Pharmacol Ther. 2007;25(5):599–608.
  • Herrick LM, Spalding WM, Saito YA, et al. A case-control comparison of direct healthcare-provider medical costs of chronic idiopathic constipation and irritable bowel syndrome with constipation in a community-based cohort. J Med Econ. 2017;20(3):273–279.
  • Chey WD, Kurlander J, Eswaran S. Irritable bowel syndrome: a clinical review. JAMA. 2015;313(9):949–958.
  • McKenzie YA, Bowyer RK, Leach H, et al. British Dietetic Association systematic review and evidence-based practice guidelines for the dietary management of irritable bowel syndrome in adults (2016 update). J Hum Nutr Diet. 2016;29(5):549–575.
  • Sonu I, Triadafilopoulos G, Gardner JD. Persistent constipation and abdominal adverse events with newer treatments for constipation. BMJ Open Gastroenterol. 2016;3(1):e000094
  • McCormick D. Managing costs and care for chronic idiopathic constipation. Am J Manag Care. 2019;25(4 Suppl):S63–S69.
  • Guerin A, Carson RT, Lewis B, et al. The economic burden of treatment failure amongst patients with irritable bowel syndrome with constipation or chronic constipation: a retrospective analysis of a Medicaid population. J Med Econ. 2014;17(8):577–586.
  • Cash BD. Understanding and managing IBS and CIC in the primary care setting. Gastroenterol Hepatol (N Y). 2018;14(5 Suppl 3):3–15.
  • Bharucha AE, Dorn SD, Lembo A, et al. American Gastroenterological Association medical position statement on constipation. Gastroenterology. 2013;144(1):211–217.
  • Tse Y, Armstrong D, Andrews CN, et al. Treatment algorithm for chronic idiopathic constipation and constipation-predominant irritable bowel syndrome derived from a Canadian national survey and needs assessment on choices of therapeutic agents. Can J Gastroenterol Hepatol. 2017;2017:8612189.
  • Buono JL, Tourkodimitris S, Sarocco P, et al. Impact of linaclotide treatment on work productivity and activity impairment in adults with irritable bowel syndrome with constipation: results from 2 randomized, double-blind, placebo-controlled phase 3 trials. Am Health Drug Benefits. 2014;7(5):289–297.
  • Solem CT, Patel H, Mehta S, et al. Treatment patterns, symptom reduction, quality of life, and resource use associated with lubiprostone in irritable bowel syndrome constipation subtype. Curr Med Res Opin. 2016;32(5):899–905.
  • Taylor DC, Abel JL, Bancroft T, et al. Health care resource use and costs pre- and post-treatment initiation with linaclotide: Retrospective analyses of a U.S. insured population. Manag Care. 2018;27(2):33–40.
  • DiBonaventura M, Sun SX, Bolge SC, et al. Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndrome. Curr Med Res Opin. 2011;27(11):2213–2222.
  • Heidelbaugh JJ, Stelwagon M, Miller SA, et al. The spectrum of constipation-predominant irritable bowel syndrome and chronic idiopathic constipation: US survey assessing symptoms, care seeking, and disease burden. Am J Gastroenterol. 2015;110(4):580–587.
  • Sun SX, Dibonaventura M, Purayidathil FW, et al. Impact of chronic constipation on health-related quality of life, work productivity, and healthcare resource use: an analysis of the National Health and Wellness Survey. Dig Dis Sci. 2011;56(9):2688–2695.
  • Stephenson JJ, Buono JL, Spalding WM, et al. Impact of irritable bowel syndrome with constipation on work productivity and daily activity among commercially insured patients in the United States. Value Health. 2014;17(7):A370.
  • Mitra D, Davis KL, Baran RW. All-cause health care charges among managed care patients with constipation and comorbid irritable bowel syndrome. Postgrad Med. 2011;123(3):122–132.
  • Mauri M, Elli T, Caviglia G, et al. RAWGraphs: a visualisation platform to create open outputs. Proceedings of the 12th Biannual Conference on Italian SIGCHI Chapter. Vol 28. New York, NY: ACM; 2017. p. 1–5.